Innovation Pharmaceuticals Inc (IPIX)

[Whoops]

Hopefully when comes to partnering its only Brilacidin and not the whole defensin-mimetic platform. Brilacidin would be the only one properly vetted to equate a value. I think the platform is stronger than most realize and to lump in the whole platform with a B deal would be to under-value the rest.

On the science-side in regards to polymed compounds their big failure was the anti-coagulant Delparantang that was not part of this platform. Interestingly though if you look at the data on D interestingly it may have the same issue that B had in the 2a trial...Dosing. I would not be surprised if Cellceutix brings up Delparantang again in the future. Either/or reformulated or alter dosing strategy.